Ampligen® (rintatolimod)
Locally Advanced Pancreatic Cancer
Key Facts
About AIM ImmunoTech
AIM ImmunoTech is a US-based public company focused on researching and developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its core asset is Ampligen® (rintatolimod), a clinical-stage immuno-modulator with approved use in Argentina for severe Chronic Fatigue Syndrome and active Phase 2 trials in pancreatic cancer. The company's strategy hinges on the broad-spectrum activity of this single platform to create value across multiple, disparate indications, though it remains pre-revenue and faces significant development and financial risks.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is a US-based public company focused on researching and developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its core asset is Ampligen® (rintatolimod), a clinical-stage immuno-modulator with approved use in Argentina for severe Chronic Fatigue Syndrome and active Phase 2 trials in pancreatic cancer. The company's strategy hinges on the broad-spectrum activity of this single platform to create value across multiple, disparate indications, though it remains pre-revenue and faces significant development and financial risks.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is a US-based public company focused on researching and developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its core asset is Ampligen® (rintatolimod), a clinical-stage immuno-modulator with approved use in Argentina for severe Chronic Fatigue Syndrome and active Phase 2 trials in pancreatic cancer. The company's strategy hinges on the broad-spectrum activity of this single platform to create value across multiple, disparate indications, though it remains pre-revenue and faces significant development and financial risks.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is a US-based public company focused on researching and developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its core asset is Ampligen® (rintatolimod), a clinical-stage immuno-modulator with approved use in Argentina for severe Chronic Fatigue Syndrome and active Phase 2 trials in pancreatic cancer. The company's strategy hinges on the broad-spectrum activity of this single platform to create value across multiple, disparate indications, though it remains pre-revenue and faces significant development and financial risks.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is a US-based public company focused on researching and developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19. Its core asset is Ampligen® (rintatolimod), a clinical-stage immuno-modulator with approved use in Argentina for severe Chronic Fatigue Syndrome and active Phase 2 trials in pancreatic cancer. The company's strategy hinges on the broad-spectrum activity of this single platform to create value across multiple, disparate indications, though it remains pre-revenue and faces significant development and financial risks.
View full company profileTherapeutic Areas
Other Locally Advanced Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| TTFields / PANOVA-3 | Novocure | Phase 3 |